In the past week, PRME stock has gone up by 4.72%, with a monthly decline of -20.83% and a quarterly plunge of -39.68%. The volatility ratio for the week is 7.37%, and the volatility levels for the last 30 days are 9.38% for Prime Medicine Inc The simple moving average for the past 20 days is 3.36% for PRME’s stock, with a -53.13% simple moving average for the past 200 days.
Is It Worth Investing in Prime Medicine Inc (NASDAQ: PRME) Right Now?
Moreover, the 36-month beta value for PRME is 1.53. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for PRME is 51.73M and currently, short sellers hold a 34.22% of that float. On June 04, 2025, PRME’s average trading volume was 1.85M shares.
PRME) stock’s latest price update
The stock price of Prime Medicine Inc (NASDAQ: PRME) has jumped by 11.76 compared to previous close of 1.19. Despite this, the company has seen a gain of 4.72% in its stock price over the last five trading days. globenewswire.com reported 2025-05-29 that CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Jefferies Global Healthcare Conference: Fireside chat on Thursday, June 5, 2025, at 10:30 a.m.
Analysts’ Opinion of PRME
Many brokerage firms have already submitted their reports for PRME stocks, with Citigroup repeating the rating for PRME by listing it as a “Neutral.” The predicted price for PRME in the upcoming period, according to Citigroup is $1.50 based on the research report published on May 27, 2025 of the current year 2025.
PRME Trading at -9.95% from the 50-Day Moving Average
After a stumble in the market that brought PRME to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.67% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PRME starting from Brudnick Richard, who purchase 20,000 shares at the price of $1.19 back on May 20 ’25. After this action, Brudnick Richard now owns 20,000 shares of Prime Medicine Inc, valued at $23,790 using the latest closing price.
LEE ANN L., the Chief Technical Officer of Prime Medicine Inc, purchase 100,000 shares at $1.13 during a trade that took place back on May 21 ’25, which means that LEE ANN L. is holding 100,000 shares at $113,000 based on the most recent closing price.
Stock Fundamentals for PRME
Current profitability levels for the company are sitting at:
- -4.96 for the present operating margin
- 0.96 for the gross margin
The net margin for Prime Medicine Inc stands at -4.85. The total capital return value is set at -0.7. Equity return is now at value -115.21, with -63.17 for asset returns.
Based on Prime Medicine Inc (PRME), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at -0.86.
Currently, EBITDA for the company is -196.34 million with net debt to EBITDA at -0.15. When we switch over and look at the enterprise to sales, we see a ratio of 4.9. The receivables turnover for the company is 2448.24for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.78.
Conclusion
To wrap up, the performance of Prime Medicine Inc (PRME) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
